0 MERS vaccine success in mice suggests potential for COVID-19 vaccine development
A vaccine against MERS has shown promise in mouse models, potentially aiding the development of a vaccine against COVID-19.
Browsing: Basic > Drug Development
0 Trial drug against COVID-19 shows promise in engineered human tissues
A new study suggests that a human recombinant soluble enzyme blocker, hrsACE2, significantly reduces SARS-CoV-2 viral load in human tissue, suggesting it could have the potential to prevent COVID-19.
0 COVID-19: Updates on vaccines and therapeutics
Take a look at our day-by-day updates covering the latest on therapeutics and vaccines for COVID-19, from new partnerships to clinical trials..
0 A peek behind the paper – Muhammad Faheem on dengue virus proteins as potential drug targets
Take a look behind the scenes of a recent Future Virology editorial entitled, ‘An insight into dengue virus proteins as potential drug/vaccine targets’, as we ask author Muhammad Faheem about recent advances in understanding dengue proteins and where the next 5–10 years could take us.
0 The race for COVID-19 treatments and vaccines: February’s industry headlines
Catch up on February’s industry headlines, including an MRSA breakthrough, a patent lawsuit, and the latest updates on the coronavirus outbreak and its impact on the biotechnology industry worldwide.
0 2020: A molecular odyssey – could artificial intelligence bring in a new age of antibiotic drug discovery?
Using machine-learning, researchers have discovered a new antibiotic that is able to kill bacteria resistant to other antibiotics.
0 AGO4: a potential new universal target for antiviral therapeutics
A team of researchers have uncovered a protein, AGO4, which may have the potential to be used as a therapeutic target to universally increase protection against viral pathogens.
0 A peek behind the paper – Blake Max on HIV integrase inhibitors
Take a look behind the scenes of a recent Future Virology article, entitled ‘Update on HIV integrase inhibitors for the treatment of HIV’, as we ask the authors about these drugs for HIV treatment and the future of this field.
0 FDA approves Merck & Co.’s Ebola vaccine Ervebo: January’s industry headlines
Take a look at the industry headlines from the last 2 months, including the FDA approval of Ebola vaccine Ervebo,…
0 New compound reverses HIV latency in macaque models
Recently, a research collaboration has managed to reverse HIV latency in infected CD4+ T cells in mouse and macaque models, exposing them to the body’s immune response.
